1. Home
  2. FKWL vs JSPR Comparison

FKWL vs JSPR Comparison

Compare FKWL & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Wireless Corp.

FKWL

Franklin Wireless Corp.

SELL

Current Price

$2.19

Market Cap

26.0M

Sector

Utilities

ML Signal

SELL

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

SELL

Current Price

$13.21

Market Cap

26.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FKWL
JSPR
Founded
1981
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.0M
26.3M
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
FKWL
JSPR
Price
$2.19
$13.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.9K
★ 412.8K
Earning Date
11-17-2026
11-17-2026
Dividend Yield
★ 1.79%
N/A
EPS Growth
N/A
★ 19.22
EPS
N/A
★ N/A
Revenue
★ $36,514,405.00
N/A
Revenue This Year
$32.55
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.12
$0.32
52 Week High
$5.19
$2.42

Technical Indicators

Market Signals
Indicator
FKWL
JSPR
Relative Strength Index (RSI) 34.36 44.90
Support Level N/A $0.45
Resistance Level $2.48 $0.67
Average True Range (ATR) 0.05 0.05
MACD -0.00 0.00
Stochastic Oscillator 0.00 57.71

Price Performance

Historical Comparison
FKWL
JSPR

About FKWL Franklin Wireless Corp.

Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics. Geographically, it derives revenue from North America, which derives maximum revenue; and Asia.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: